As the interaction with polyvalent antigen, followed by crosslinking of FcεRI, leads to the strong activation of mast cells and basophils, this molecule as an IgE ligand is considered a target for the development of biologics for the treatment of allergic disease, including atopic dermatitis, seasonal rhinitis, urticaria, life-threatening anaphylaxis, and prolonged inflammation leading to chronic conditions, such as asthma. This evidence concerns the gene IGHE and allergic disease.